Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer

Biochemical Pharmacology

Volumn 80, Issue 5, 2010, Pages 683-689

  Yi, Chunling ^a   Maksimoska, Jasna ^a   Marmorstein, Ronen ^a   Kissil, Joseph L ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Breast cancer; Kinase inhibitors; Neurofibromatosis; Organometallic; P21 activated kinases

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; CELECOXIB; CEP 1347; DW 12; ENZYME INHIBITOR; FL 172; GUANINE NUCLEOTIDE BINDING PROTEIN; IPA 3; KS52A; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE INHIBITOR; PROTEIN CDC42; STAUROSPORINE; UNCLASSIFIED DRUG;

ALLOSTERISM; BREAST CARCINOMA; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IC 50; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; P21-ACTIVATED KINASES; PROTEIN KINASE INHIBITORS;

EID: 77954216859     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.012     Document Type: Review

References (70)

1. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992, 70:401-410.
2. Nobes C.D., Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81:53-62.
3. Dummler B., Ohshiro K., Kumar R., Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009, 28:51-63.
4. Molli P.R., Li D.Q., Murray B.W., Rayala S.K., Kumar R. PAK signaling in oncogenesis. Oncogene 2009, 28:2545-2555.
5. Arias-Romero L.E., Chernoff J. A tale of two Paks. Biol Cell 2008, 100:97-108.
6. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
7. Bishop A.L., Hall A. Rho GTPases and their effector proteins. Biochem J 2000, 348(Pt 2):241-255.
8. Lei M., Lu W., Meng W., Parrini M.C., Eck M.J., Mayer B.J., et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 2000, 102:387-397.
9. Parrini M.C., Lei M., Harrison S.C., Mayer B.J. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell 2002, 9:73-83.
10. Frost J.A., Khokhlatchev A., Stippec S., White M.A., Cobb M.H. Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation. J Biol Chem 1998, 273:28191-28198.
11. Zhao Z.S., Manser E., Chen X.Q., Chong C., Leung T., Lim L. A conserved negative regulatory region in alphaPAK: inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. Mol Cell Biol 1998, 18:2153-2163.
12. Zenke F.T., King C.C., Bohl B.P., Bokoch G.M. Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity. J Biol Chem 1999, 274:32565-32573.
13. Lei M., Robinson M.A., Harrison S.C. The active conformation of the PAK1 kinase domain. Structure 2005, 13:769-778.
14. Wells C.M., Jones G.E. The emerging importance of group II PAKs. Biochem J 2010, 425:465-473.
15. Eswaran J., Soundararajan M., Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 2009, 28:209-217.
16. Brown M.C., Cary L.A., Jamieson J.S., Cooper J.A., Turner C.E. Src and FAK kinases cooperate to phosphorylate paxillin kinase linker, stimulate its focal adhesion localization, and regulate cell spreading and protrusiveness. Mol Biol Cell 2005, 16:4316-4328.
17. Cau J., Hall A. Cdc42 controls the polarity of the actin and microtubule cytoskeletons through two distinct signal transduction pathways. J Cell Sci 2005, 118:2579-2587.
18. Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E. The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell 2005, 20:237-249.
19. Maroto B., Ye M.B., von Lohneysen K., Schnelzer A., Knaus U.G. P21-activated kinase is required for mitotic progression and regulates Plk1. Oncogene 2008, 27:4900-4908.
20. Beeser A., Jaffer Z.M., Hofmann C., Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem 2005, 280:36609-36615.
21. Tran N.H., Frost J.A. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 2003, 278:11221-11226.
22. Sastry K.S., Karpova Y., Kulik G. Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 2006, 281:27367-27377.
23. Jin S., Zhuo Y., Guo W., Field J. p21-activated kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 2005, 280:24698-24705.
24. Schurmann A., Mooney A.F., Sanders L.C., Sells M.A., Wang H.G., Reed J.C., et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 2000, 20:453-461.
25. Vadlamudi R.K., Bagheri-Yarmand R., Yang Z., Balasenthil S., Nguyen D., Sahin A.A., et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004, 5:575-585.
26. Mazumdar A., Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 2003, 535:6-10.
27. Kumar R., Vadlamudi R.K. Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol 2002, 193:133-144.
28. Balasenthil S., Sahin A.A., Barnes C.J., Wang R.A., Pestell R.G., Vadlamudi R.K., et al. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2004, 279:1422-1428.
29. Wang R.A., Zhang H., Balasenthil S., Medina D., Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006, 25:2931-2936.
30. Vadlamudi R.K., Adam L., Wang R.A., Mandal M., Nguyen D., Sahin A., et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000, 275:36238-36244.
31. Adam L., Vadlamudi R., Mandal M., Chernoff J., Kumar R. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 2000, 275:12041-12050.
32. Adam L., Vadlamudi R., Kondapaka S.B., Chernoff J., Mendelsohn J., Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998, 273:28238-28246.
33. Li Q., Mullins S.R., Sloane B.F., Mattingly R.R. p21-activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia 2008, 10:314-329.
34. Rayala S.K., Talukder A.H., Balasenthil S., Tharakan R., Barnes C.J., Wang R.A., et al. p21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006, 66:1694-1701.
35. Holm C., Rayala S., Jirstrom K., Stal O., Kumar R., Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006, 98:671-680.
36. Bostner J., Ahnstrom Waltersson M., Fornander T., Skoog L., Nordenskjold B., Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007, 26:6997-7005.
37. Gerber P.A., Antal A.S., Neumann N.J., Homey B., Matuschek C., Peiper M., et al. Neurofibromatosis. Eur J Med Res 2009, 14:102-105.
38. Tsakiridis T., Taha C., Grinstein S., Klip A. Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase. J Biol Chem 1996, 271:19664-19667.
39. Slack-Davis J.K., Eblen S.T., Zecevic M., Boerner S.A., Tarcsafalvi A., Diaz H.B., et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 2003, 162:281-291.
40. Chaudhary A., King W.G., Mattaliano M.D., Frost J.A., Diaz B., Morrison D.K., et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 2000, 10:551-554.
41. King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 1998, 396:180-183.
42. Hirokawa Y., Tikoo A., Huynh J., Utermark T., Hanemann C.O., Giovannini M., et al. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004, 10:20-26.
43. Kissil J.L., Wilker E.W., Johnson K.C., Eckman M.S., Yaffe M.B., Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003, 12:841-849.
44. Xiao G.H., Gallagher R., Shetler J., Skele K., Altomare D.A., Pestell R.G., et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005, 25:2384-2394.
45. Wilkes M.C., Repellin C.E., Hong M., Bracamonte M., Penheiter S.G., Borg J.P., et al. Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. Dev Cell 2009, 16:433-444.
46. Ingram D.A., Hiatt K., King A.J., Fisher L., Shivakumar R., Derstine C., et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001, 194:57-69.
47. Yi C., Wilker E.W., Yaffe M.B., Stemmer-Rachamimov A., Kissil J.L. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res 2008, 68:7932-7937.
48. Tang Y., Chen Z., Ambrose D., Liu J., Gibbs J.B., Chernoff J., et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997, 17:4454-4464.
49. Yang F.C., Ingram D.A., Chen S., Hingtgen C.M., Ratner N., Monk K.R., et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 2003, 112:1851-1861.
50. Zhu Y., Ghosh P., Charnay P., Burns D.K., Parada L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922.
51. Yang F.C., Ingram D.A., Chen S., Zhu Y., Yuan J., Li X., et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 2008, 135:437-448.
52. McDaniel A.S., Allen J.D., Park S.J., Jaffer Z.M., Michels E.G., Burgin S.J., et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood 2008, 112:4646-4654.
53. Nakai Y., Zheng Y., MacCollin M., Ratner N. Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci 2006, 26:3390-3395.
54. Kaempchen K., Mielke K., Utermark T., Langmesser S., Hanemann C.O. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 2003, 12:1211-1221.
55. Flaiz C., Kaempchen K., Matthies C., Hanemann C.O. Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. J Neuropathol Exp Neurol 2007, 66:608-616.
56. Xiao G.H., Beeser A., Chernoff J., Testa J.R. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002, 277:883-886.
57. Kissil J.L., Johnson K.C., Eckman M.S., Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002, 277:10394-10399.
58. Morrison H., Sperka T., Manent J., Giovannini M., Ponta H., Herrlich P. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007, 67:520-527.
59. Flaiz C., Chernoff J., Ammoun S., Peterson J.R., Hanemann C.O. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol 2009, 218:137-144.
60. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007, 408:297-315.
61. Ghoreschi K., Laurence A., O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol 2009, 10:356-360.
62. Kaneko M., Saito Y., Saito H., Matsumoto T., Matsuda Y., Vaught J.L., et al. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J Med Chem 1997, 40:1863-1869.
63. Nheu T.V., He H., Hirokawa Y., Tamaki K., Florin L., Schmitz M.L., et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 2002, 8:328-336.
64. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight E., Murphy C.A., et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998, 18:104-111.
65. Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., et al. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001, 276:25302-25308.
66. Zhu J., Huang J.-W., Tseng P.-H., Yang Y.-T., Fowble J., Shiau C.-W., et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004, 64:4309-4318.
67. Porchia L.M., Guerra M., Wang Y.C., Zhang Y., Espinosa A.V., Shinohara M., et al. 2-Amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007, 72:1124-1131.
68. Maksimoska J., Feng L., Harms K., Yi C., Kissil J., Marmorstein R., et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 2008, 130:15764-15765.
69. Deacon S.W., Beeser A., Fukui J.A., Rennefahrt U.E., Myers C., Chernoff J., et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008, 15:322-331.
70. Viaud J., Peterson J.R. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009, 8:2559-2565.